Q-omics provides the consensus-scored DTWD1 profile across patient tissues and cancer cell-line models. DTWD1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, DTWD1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, DTWD1 RNA expression shows 20,892 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight SCLC, THCA, and KIRP as cancer lineages where DTWD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DTWD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DTWD1 survival associations across molecular data types. DTWD1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DTWD1 RNA expression–survival associations across cancer types. High DTWD1 expression shows unfavorable associations in SCLC and KIRP, but favorable associations in UCEC, KIRC, UVM and UCS. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify SCLC as the clearest survival context for DTWD1 RNA expression.
This table summarizes DTWD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DTWD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DTWD1 shows lower tumor expression in THCA, UCEC, BLCA, BRCA and KICH and higher tumor expression in LIHC. The THCA box plot shows higher DTWD1 RNA expression in normal versus tumor tissue (log2 FC = −0.805, t-test p < 0.001).
This table shows molecular features associated with DTWD1 in patient tissues and cancer cell lines. In patient samples, DTWD1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, DTWD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
